| |
| |
| Exchange: |
OTC Bulletin Board |
| Security
Type: |
Common |
| Shares
Out: |
66,230,000 |
| Market
Cap: |
4.11(M) |
| Last
Volume: |
362,100 |
Avg
Vol: |
361,085 |
| 52
Week Range: |
$0.062 - $0.062 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Advaxis is a clinical-stage biotechnology company focused on the development and commercialization of proprietary Listeria monocytogenes (Lm) Technology antigen delivery products based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins. Co.'s pipeline of product candidates include: ADXS-503, which is for the cancer indication of non-small cell lung cancer in combination with KEYTRUDA® (pembrolizumab); ADXS-504, which is for the cancer indication of early stage prostate cancer; and ADXS-PSA, which is for the cancer indication of metastatic prostate cancer in combination with KEYTRUDA® (pembrolizumab).
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
1,317,716 |
1,317,716 |
1,317,716 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
1 |
1 |
1 |
| Total Buy Transactions |
0 |
1 |
1 |
1 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-01-18 |
2023-10-17 |
2023-04-18 |
2022-04-18 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  I.b.f. Management Ltd. |
Director |
– • • |
2024-02-07 |
4 |
D |
$1.25 |
$6,599,577 |
I/I |
(5,294,486) |
25,130,903 |
|
- |
|
| I.b.f. Management Ltd. |
Director |
– • • |
2024-02-07 |
4 |
OE |
$0.40 |
$11,138,864 |
I/I |
27,847,159 |
27,717,808 |
|
- |
|
| Cabilly Yuval |
|
– • – |
2023-10-18 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,298,639 |
|
- |
|
| I.b.f. Management Ltd. |
10% Owner |
– – • |
2023-10-18 |
4 |
B |
$0.00 |
$0 |
I/I |
1,317,716 |
1,094,091 |
1.42 |
- |
|
| Amoon 2 Fund Limited Partnership |
10% Owner |
– – • |
2023-10-18 |
4 |
D |
$0.00 |
$0 |
D/D |
(0) |
560,602 |
|
- |
|
| I.b.f. Management Ltd. |
10% Owner |
– – • |
2023-01-19 |
3/A |
IO |
$0.00 |
$0 |
I/I |
0 |
621,253 |
|
- |
|
| Israel Biotech Fund I, L.p. |
10% Owner |
– – • |
2023-01-19 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
621,253 |
|
- |
|
| Schindel Yair Chaim |
10% Owner |
– – • |
2023-01-19 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
560,602 |
|
- |
|
| Sidransky David |
Director |
– • – |
2023-01-19 |
4 |
A |
$0.00 |
$0 |
I/I |
46 |
46 |
|
- |
|
| Appel Roni |
Director |
– • – |
2020-03-13 |
4 |
S |
$0.55 |
$1,321 |
I/I |
(2,401) |
10,476 |
|
-18% |
|
| Appel Roni |
Director |
– • – |
2020-03-12 |
4 |
S |
$0.58 |
$116 |
I/I |
(200) |
12,877 |
|
-14% |
|
| Appel Roni |
Director |
– • – |
2020-03-11 |
4 |
S |
$0.67 |
$267 |
I/I |
(399) |
13,077 |
|
6% |
|
| Gutierrez Andres |
Executive Vice President & CMO |
• – – |
2019-04-11 |
4 |
A |
$3.71 |
$13,928 |
D/D |
3,750 |
3,750 |
|
- |
|
| Henderson Molly |
Executive Vice President & CFO |
• – – |
2019-04-11 |
4 |
A |
$3.68 |
$9,200 |
D/D |
2,500 |
5,833 |
|
- |
|
| Appel Roni |
Director |
– • – |
2019-04-10 |
4 |
B |
$3.80 |
$11,391 |
I/I |
3,000 |
13,476 |
2.1 |
- |
|
| Henderson Molly |
Executive Vice President & CFO |
• – – |
2019-04-09 |
4 |
A |
$3.85 |
$11,579 |
D/D |
3,000 |
100 |
|
- |
|
| Berlin Kenneth A |
President & CEO |
• • – |
2019-04-08 |
4 |
A |
$3.78 |
$15,112 |
D/D |
4,000 |
800 |
|
- |
|
| Petit Robert |
Chief Scientific Officer |
• – – |
2018-11-05 |
4 |
S |
$0.58 |
$2,299 |
D/D |
(3,963) |
231,206 |
|
- |
|
| Appel Roni |
Director |
– • – |
2018-09-11 |
4 |
B |
$1.20 |
$40,000 |
I/I |
33,333 |
157,143 |
2.1 |
- |
|
| Petit Robert |
Chief Scientific Officer |
• – – |
2018-07-31 |
4 |
A |
$1.46 |
$2,197 |
D/D |
1,505 |
243,660 |
|
- |
|
| Petit Robert |
Chief Scientific Officer |
• – – |
2018-06-29 |
4 |
A |
$1.45 |
$2,198 |
D/D |
1,516 |
242,155 |
|
- |
|
| Sidransky David |
Director |
– • – |
2018-06-26 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
110,355 |
|
- |
|
| Berman Richard J |
Director |
– • – |
2018-06-26 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
55,669 |
|
- |
|
| Patton James P |
Director |
– • – |
2018-06-26 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
286,749 |
|
- |
|
| Petit Robert |
Chief Scientific Officer |
• – – |
2018-06-18 |
4 |
A |
$1.72 |
$15,480 |
D/D |
9,000 |
240,639 |
|
- |
|
465 Records found
|
|
Page 1 of 19 |
|
|
